Abstract

Spitzoid neoplasms are a distinct group of melanocytic proliferations characterized by epithelioid and/ or spindle shaped melanocytes. Intermediate forms that share features of both benign Spitz nevi (SN) and Spitz melanoma, i.e., malignant Spitz tumor (MST) represent a diagnostically and clinically challenging group of melanocytic lesions. A multitude of descriptive diagnostic terms exist for these ambiguous lesions with atypical Spitz tumor (AST) or Spitz tumor of uncertain malignant potential (STUMP) just naming two of them. This diagnostic gray zone creates confusion and high insecurity in clinicians and in patients. Biological behavior and clinical course of this intermediate group still remains largely unknown, often leading to difficulties with uncertainties in clinical management and prognosis. Consequently, a better stratification of Spitzoid neoplasms in benign and malignant forms is required thereby keeping the diagnostic group of AST/STUMP as small as possible. Ancillary diagnostic techniques such as immunohistochemistry, comparative genomic hybridization, fluorescence in situ hybridization, next generation sequencing, micro RNA and mRNA analysis as well as mass spectrometry imaging offer new opportunities for the distinct diagnosis, thereby allowing the best clinical management of Spitzoid neoplasms. This review gives an overview on these additional diagnostic techniques and the recent developments in the field of molecular genetic alterations in Spitzoid neoplasms. We also discuss how the recent findings might facilitate the diagnosis and stratification of atypical Spitzoid neoplasms and how these findings will impact the diagnostic work up as well as patient management. We suggest a stepwise implementation of ancillary diagnostic techniques thereby integrating immunohistochemistry and molecular pathology findings in the diagnosis of challenging ambiguous Spitzoid neoplasms. Finally, we will give an outlook on pending future research objectives in the field of Spitzoid melanocytic lesions.

Highlights

  • AND BACKGROUNDMelanocytic neoplasms comprise a heterogeneous group of tumors that are characterized by their distinct histopathological appearance, their clinical features and their genetic aberrations

  • The current data are derived from a limited number of cases with only limited long term follow up the results suggest that HRAS mutations in Spitzoid lesions can be attributed to a benign biological behavior

  • Conformational studies are pending, these findings strongly suggest that there may be some characteristics on molecular level that are detected by Mass Spectrometry Imaging (MSI) to better distinguish the gray zone AST category beyond the information provided by histopathology or immunohistochemistry

Read more

Summary

Introduction

AND BACKGROUNDMelanocytic neoplasms comprise a heterogeneous group of tumors that are characterized by their distinct histopathological appearance, their clinical features and their genetic aberrations. The current data are derived from a limited number of cases with only limited long term follow up the results suggest that HRAS mutations in Spitzoid lesions can be attributed to a benign biological behavior. Fusions such as translocations of the receptor tyrosine kinases including ALK, ROS1, NTRK1, NTRK3, RET, and MET are found in up to 50% of Spitz tumors and are infrequent in conventional melanocytic lesions with BRAF mutations [6, 56, 64, 65].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call